Literature DB >> 1149326

The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels.

S N Anavekar, W J Louis, T O Morgan, A E Doyle, C I Johnston.   

Abstract

1. Fifteen, previously untreated, hypertensive patients were given 20 mg of pindolol, orally. The systolic and diastolic blood pressures fell significantly in 1 h; the effect was maximal 4 h after pindolol, and persisted for at least 8 h. 2. After oral administration of 20 mg of pindolol, its concentration in the plasma reached a peak in 2-3 h. At the end of 8 h, pindolol was not detectable in the plasma. 3. There was a significant relationship between the peak concentration of pindolol in plasma and the maximal change in blood pressure in fifteen previously untreated hypertensive patients. In a separate study of nine-nine hypertensive outpatients taking 15-80 mg of pindolol daily, the blood pressure responses corresponded generally to the concentration of pindolol in plasma 2-3 h after the morning dose. 4. There were no significant changes in plasma renin activity, plasma renin concentration or plasma noradrenaline concentration in the previously untreated patients taking 20 mg of pindolol. There was no relationship between initial plasma renin or noradrenaline levels and blood pressure responses to pindolol. Nor was there any significant relationship between the changes in plasma renin or noradrenaline levels and the changes in blood pressure.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1149326     DOI: 10.1111/j.1440-1681.1975.tb03026.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  24 in total

1.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 2.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

Review 3.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 4.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 5.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

6.  Acebutolol in hypertension: relationships between drug concentration and effects.

Authors:  M A Martin; F C Phillips; G T Tucker; A J Smith
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

7.  Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol. I. Effect on maximal working capacity, plasma catecholamines and renin, Urinary aldosterone, blood pressure and pulse rate under basal conditions.

Authors:  B G Hansson; J F Dymling; H Hedeland; U L Hulthén
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

8.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

9.  Dissociation between duration of plasma catecholamine and blood pressure responses to beta-adrenergic blockade in normotensive subjects during physical exercise.

Authors:  G Planz; R Planz
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

Review 10.  Effect of antihypertensive drugs on the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1976       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.